| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| AAH1 | ADE1 | YNL141W | YAR015W | Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded upon entry into quiescence via SCF and the proteasome. | Phosphoribosylaminoimidazole-succinocarboxamide synthase; N-succinyl-5-aminoimidazole-4-carboxamide ribotide synthetase; required for 'de novo' purine nucleotide biosynthesis; red pigment accumulates in mutant cells deprived of adenine; protein abundance increases in response to DNA replication stress. | 0.470 |
| AAH1 | ADE17 | YNL141W | YMR120C | Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded upon entry into quiescence via SCF and the proteasome. | Phosphoribosylaminoimidazolecarboxamide formyltransferase; Enzyme of 'de novo' purine biosynthesis; contains both 5-aminoimidazole-4-carboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrolase activities; ADE17 has a paralog, ADE16, that arose from the whole genome duplication; ade16 ade17 mutants require adenine and histidine; Belongs to the PurH family. | 0.614 |
| AAH1 | FCY1 | YNL141W | YPR062W | Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded upon entry into quiescence via SCF and the proteasome. | Cytosine deaminase; zinc metalloenzyme that catalyzes the hydrolytic deamination of cytosine to uracil; of biomedical interest because it also catalyzes the deamination of 5-fluorocytosine (5FC) to form anticancer drug 5-fluorouracil (5FU); Belongs to the cytidine and deoxycytidylate deaminase family. | 0.461 |
| AAH1 | FCY2 | YNL141W | YER056C | Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded upon entry into quiescence via SCF and the proteasome. | Purine-cytosine permease; mediates purine (adenine, guanine, and hypoxanthine) and cytosine accumulation; relative distribution to the vacuole increases upon DNA replication stress. | 0.695 |
| AAH1 | FUR1 | YNL141W | YHR128W | Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded upon entry into quiescence via SCF and the proteasome. | Uracil phosphoribosyltransferase; synthesizes UMP from uracil; involved in the pyrimidine salvage pathway. | 0.498 |
| AAH1 | HPT1 | YNL141W | YDR399W | Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded upon entry into quiescence via SCF and the proteasome. | Dimeric hypoxanthine-guanine phosphoribosyltransferase; catalyzes the transfer of the phosphoribosyl portion of 5-phosphoribosyl-alpha-1-pyrophosphate to a purine base (either guanine or hypoxanthine) to form pyrophosphate and a purine nucleotide (either guanosine monophosphate or inosine monophosphate); mutations in the human homolog HPRT1 can cause Lesch-Nyhan syndrome and Kelley-Seegmiller syndrome. | 0.989 |
| ADE1 | AAH1 | YAR015W | YNL141W | Phosphoribosylaminoimidazole-succinocarboxamide synthase; N-succinyl-5-aminoimidazole-4-carboxamide ribotide synthetase; required for 'de novo' purine nucleotide biosynthesis; red pigment accumulates in mutant cells deprived of adenine; protein abundance increases in response to DNA replication stress. | Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded upon entry into quiescence via SCF and the proteasome. | 0.470 |
| ADE1 | ADE17 | YAR015W | YMR120C | Phosphoribosylaminoimidazole-succinocarboxamide synthase; N-succinyl-5-aminoimidazole-4-carboxamide ribotide synthetase; required for 'de novo' purine nucleotide biosynthesis; red pigment accumulates in mutant cells deprived of adenine; protein abundance increases in response to DNA replication stress. | Phosphoribosylaminoimidazolecarboxamide formyltransferase; Enzyme of 'de novo' purine biosynthesis; contains both 5-aminoimidazole-4-carboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrolase activities; ADE17 has a paralog, ADE16, that arose from the whole genome duplication; ade16 ade17 mutants require adenine and histidine; Belongs to the PurH family. | 0.996 |
| ADE1 | FCY2 | YAR015W | YER056C | Phosphoribosylaminoimidazole-succinocarboxamide synthase; N-succinyl-5-aminoimidazole-4-carboxamide ribotide synthetase; required for 'de novo' purine nucleotide biosynthesis; red pigment accumulates in mutant cells deprived of adenine; protein abundance increases in response to DNA replication stress. | Purine-cytosine permease; mediates purine (adenine, guanine, and hypoxanthine) and cytosine accumulation; relative distribution to the vacuole increases upon DNA replication stress. | 0.676 |
| ADE1 | HPT1 | YAR015W | YDR399W | Phosphoribosylaminoimidazole-succinocarboxamide synthase; N-succinyl-5-aminoimidazole-4-carboxamide ribotide synthetase; required for 'de novo' purine nucleotide biosynthesis; red pigment accumulates in mutant cells deprived of adenine; protein abundance increases in response to DNA replication stress. | Dimeric hypoxanthine-guanine phosphoribosyltransferase; catalyzes the transfer of the phosphoribosyl portion of 5-phosphoribosyl-alpha-1-pyrophosphate to a purine base (either guanine or hypoxanthine) to form pyrophosphate and a purine nucleotide (either guanosine monophosphate or inosine monophosphate); mutations in the human homolog HPRT1 can cause Lesch-Nyhan syndrome and Kelley-Seegmiller syndrome. | 0.656 |
| ADE17 | AAH1 | YMR120C | YNL141W | Phosphoribosylaminoimidazolecarboxamide formyltransferase; Enzyme of 'de novo' purine biosynthesis; contains both 5-aminoimidazole-4-carboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrolase activities; ADE17 has a paralog, ADE16, that arose from the whole genome duplication; ade16 ade17 mutants require adenine and histidine; Belongs to the PurH family. | Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded upon entry into quiescence via SCF and the proteasome. | 0.614 |
| ADE17 | ADE1 | YMR120C | YAR015W | Phosphoribosylaminoimidazolecarboxamide formyltransferase; Enzyme of 'de novo' purine biosynthesis; contains both 5-aminoimidazole-4-carboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrolase activities; ADE17 has a paralog, ADE16, that arose from the whole genome duplication; ade16 ade17 mutants require adenine and histidine; Belongs to the PurH family. | Phosphoribosylaminoimidazole-succinocarboxamide synthase; N-succinyl-5-aminoimidazole-4-carboxamide ribotide synthetase; required for 'de novo' purine nucleotide biosynthesis; red pigment accumulates in mutant cells deprived of adenine; protein abundance increases in response to DNA replication stress. | 0.996 |
| ADE17 | FCY2 | YMR120C | YER056C | Phosphoribosylaminoimidazolecarboxamide formyltransferase; Enzyme of 'de novo' purine biosynthesis; contains both 5-aminoimidazole-4-carboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrolase activities; ADE17 has a paralog, ADE16, that arose from the whole genome duplication; ade16 ade17 mutants require adenine and histidine; Belongs to the PurH family. | Purine-cytosine permease; mediates purine (adenine, guanine, and hypoxanthine) and cytosine accumulation; relative distribution to the vacuole increases upon DNA replication stress. | 0.700 |
| ADE17 | HPT1 | YMR120C | YDR399W | Phosphoribosylaminoimidazolecarboxamide formyltransferase; Enzyme of 'de novo' purine biosynthesis; contains both 5-aminoimidazole-4-carboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrolase activities; ADE17 has a paralog, ADE16, that arose from the whole genome duplication; ade16 ade17 mutants require adenine and histidine; Belongs to the PurH family. | Dimeric hypoxanthine-guanine phosphoribosyltransferase; catalyzes the transfer of the phosphoribosyl portion of 5-phosphoribosyl-alpha-1-pyrophosphate to a purine base (either guanine or hypoxanthine) to form pyrophosphate and a purine nucleotide (either guanosine monophosphate or inosine monophosphate); mutations in the human homolog HPRT1 can cause Lesch-Nyhan syndrome and Kelley-Seegmiller syndrome. | 0.985 |
| FCY1 | AAH1 | YPR062W | YNL141W | Cytosine deaminase; zinc metalloenzyme that catalyzes the hydrolytic deamination of cytosine to uracil; of biomedical interest because it also catalyzes the deamination of 5-fluorocytosine (5FC) to form anticancer drug 5-fluorouracil (5FU); Belongs to the cytidine and deoxycytidylate deaminase family. | Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded upon entry into quiescence via SCF and the proteasome. | 0.461 |
| FCY1 | FCY2 | YPR062W | YER056C | Cytosine deaminase; zinc metalloenzyme that catalyzes the hydrolytic deamination of cytosine to uracil; of biomedical interest because it also catalyzes the deamination of 5-fluorocytosine (5FC) to form anticancer drug 5-fluorouracil (5FU); Belongs to the cytidine and deoxycytidylate deaminase family. | Purine-cytosine permease; mediates purine (adenine, guanine, and hypoxanthine) and cytosine accumulation; relative distribution to the vacuole increases upon DNA replication stress. | 0.944 |
| FCY1 | FKS1 | YPR062W | YLR342W | Cytosine deaminase; zinc metalloenzyme that catalyzes the hydrolytic deamination of cytosine to uracil; of biomedical interest because it also catalyzes the deamination of 5-fluorocytosine (5FC) to form anticancer drug 5-fluorouracil (5FU); Belongs to the cytidine and deoxycytidylate deaminase family. | 1,3-beta-glucan synthase component FKS1; Catalytic subunit of 1,3-beta-D-glucan synthase; functionally redundant with alternate catalytic subunit Gsc2p; binds to regulatory subunit Rho1p; involved in cell wall synthesis and maintenance; localizes to sites of cell wall remodeling; FKS1 has a paralog, GSC2, that arose from the whole genome duplication. | 0.689 |
| FCY1 | FUR1 | YPR062W | YHR128W | Cytosine deaminase; zinc metalloenzyme that catalyzes the hydrolytic deamination of cytosine to uracil; of biomedical interest because it also catalyzes the deamination of 5-fluorocytosine (5FC) to form anticancer drug 5-fluorouracil (5FU); Belongs to the cytidine and deoxycytidylate deaminase family. | Uracil phosphoribosyltransferase; synthesizes UMP from uracil; involved in the pyrimidine salvage pathway. | 0.995 |
| FCY1 | FUR4 | YPR062W | YBR021W | Cytosine deaminase; zinc metalloenzyme that catalyzes the hydrolytic deamination of cytosine to uracil; of biomedical interest because it also catalyzes the deamination of 5-fluorocytosine (5FC) to form anticancer drug 5-fluorouracil (5FU); Belongs to the cytidine and deoxycytidylate deaminase family. | Uracil permease; Plasma membrane localized uracil permease; expression is tightly regulated by uracil levels and environmental cues; conformational alterations induced by unfolding or substrate binding result in Rsp5p-mediated ubiquitination and degradation. | 0.515 |
| FCY2 | AAH1 | YER056C | YNL141W | Purine-cytosine permease; mediates purine (adenine, guanine, and hypoxanthine) and cytosine accumulation; relative distribution to the vacuole increases upon DNA replication stress. | Adenine deaminase (adenine aminohydrolase); converts adenine to hypoxanthine; involved in purine salvage; transcriptionally regulated by nutrient levels and growth phase; Aah1p degraded upon entry into quiescence via SCF and the proteasome. | 0.695 |
